No Data
No Data
Institutional Investors Own a Significant Stake of 39% in Abeona Therapeutics Inc. (NASDAQ:ABEO)
H.C. Wainwright Maintains Abeona Therapeutics(ABEO.US) With Buy Rating, Maintains Target Price $15
H.C. Wainwright analyst Ram Selvaraju maintains $Abeona Therapeutics(ABEO.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 42
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $15 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $15 price target.
Abeona Therapeutics Partners With Beacon Therapeutics to Develop Ophthalmic Gene Therapies
Abeona Therapeutics (ABEO) said Thursday it entered into an exclusive agreement with Beacon Therapeutics to evaluate its patented AAV204 capsid to potentially develop and market gene therapies for
Express News | Abeona Therapeutics: To Get Upfront Payment Upon Beacon's Exercise of Option to License Aav204, With Extra Payments on Achievement of Milestones
Express News | Abeona Therapeutics: Beacon to Have Right to Use Aav204 for up to 4 Additional Nominated Gene or Disease Targets Subject to Certain Conditions